Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed), eta | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.2652 | 0.2652 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.2652 | 0.1904 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.2652 | 0.2652 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 1 | 1 |
Schistosoma mansoni | DNA polymerase eta | 0.0054 | 1 | 1 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0038 | 0.6161 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0054 | 1 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0038 | 0.6161 | 0.4775 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0012 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.2652 | 0.5 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 0.2652 | 0.2652 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0038 | 0.6161 | 0.4775 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.2652 | 0.5 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 0.2652 | 0.2652 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.2652 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.2652 | 0.5 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.2652 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.2652 | 0.1904 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.2652 | 0.2652 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.2652 | 0.5 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Echinococcus multilocularis | dna polymerase eta | 0.0054 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.2652 | 0.5 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 0.2652 | 0.2652 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0.2652 | 0.2652 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.2652 | 0.1904 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.2652 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.2652 | 0.1904 |
Leishmania major | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.2652 | 0.1904 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 0.2652 | 0.2652 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 7.0795 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 75.6863 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.